Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High – Still a Buy?

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $38.42 and last traded at $38.5010, with a volume of 862605 shares. The stock had previously closed at $37.09.

Analyst Ratings Changes

Several research firms have recently commented on TEVA. UBS Group increased their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Leerink Partners began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Ten analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.10.

Teva Pharmaceutical Industries Trading Up 5.4%

The stock has a market cap of $45.57 billion, a P/E ratio of 65.18, a price-to-earnings-growth ratio of 4.62 and a beta of 0.87. The firm’s 50 day simple moving average is $34.91 and its two-hundred day simple moving average is $33.37. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC raised its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after buying an additional 302 shares during the period. Banque Cantonale Vaudoise grew its position in Teva Pharmaceutical Industries by 6.3% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after buying an additional 306 shares in the last quarter. Allworth Financial LP increased its stake in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.